Serum Levels of Fibroblast Growth Factor 19 Correlate with the Severity of Diarrhea and Independently from Intestinal Inflammation in Patients with Inflammatory Bowel Disease or Microscopic Colitis

2021 ◽  
Vol 32 (4) ◽  
pp. 374-381
Author(s):  
Ivan Lyutakov ◽  
◽  
Radislav Nakov ◽  
Hristo Valkov ◽  
Rositsa Vatcheva-Dobrevska ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Bowel Disease ◽  
Intestinal Inflammation ◽  
Serum Levels ◽  
Microscopic Colitis ◽  
Fibroblast Growth ◽  
Inflammatory Bowel ◽  
Fibroblast Growth Factor 19

scholarly journals Fibroblast growth factor 23 contributes to diminished bone mineral density in childhood inflammatory bowel disease

2012 ◽  
Vol 12 (1) ◽  
Author(s):  
Mostafa Abdel-Aziz El-Hodhod ◽  
Ahmad Mohamed Hamdy ◽  
Amal Ahmed Abbas ◽  
Sherine George Moftah ◽  
Alhag Ahmed Mohamed Ramadan
Keyword(s):  
Bone Mineral Density ◽  
Inflammatory Bowel Disease ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Bone Mineral ◽  
Bowel Disease ◽  
Fibroblast Growth Factor 23 ◽  
Fibroblast Growth ◽  
Mineral Density ◽  
Inflammatory Bowel

scholarly journals Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Takahiro Maeda ◽  
Hiroaki Kanzaki ◽  
Tetsuhiro Chiba ◽  
Junjie Ao ◽  
Kengo Kanayama ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Serum Levels ◽  
Diagnostic Value ◽  
Enzyme Linked Immunosorbent Assay ◽  
Fibroblast Growth ◽  
Ablation Therapy ◽  
Receiver Operating Characteristic Curves ◽  
Fibroblast Growth Factor 19

Abstract Background Abnormal autocrine fibroblast growth factor 19 (FGF19) production has been observed in several types of cancers, including hepatocellular carcinoma (HCC). In this study, we investigated the potential of serum FGF19 as a novel tumor marker of HCC based on a sandwich enzyme-linked immunosorbent assay (ELISA). Methods The serum FGF19 levels of 304 patients with HCC was measured by ELISA. The serum levels of existing markers, including alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) were determined by chemiluminescence enzyme immunoassay. Both diagnostic value of FGF19 and its changes after curative ablation therapy was further examined. Results The median FGF19 levels in controls, chronic liver disease patients, and primary HCC patients, were 78.8 pg/mL, 100.1 pg/mL, and 214.5 pg/mL, respectively. The subsequent receiver operating characteristic curves (ROC) successfully determined an optimal cut-off value of 200.0 pg/mL. The area under the ROC curve (AUC) of FGF19 for HCC detection was comparable to those of AFP and DCP. Of importance, FGF19 showed higher sensitivity for the detection of small HCC (solitary cancer with diameter < 20 mm) than those of existing markers. In addition, 43 out of 79 cases (54.4%) with normal AFP and DCP (so-called “double negative HCC”) exhibited serum FGF19 level ≥ 200 pg/mL. In 45 HCC patients treated with curative ablation therapy, serum FGF19 levels changed from 257.4 pg/mL to 112.0 pg/mL after the treatment. Conclusion Our findings reveal that FGF19 can be a potential novel biomarker for HCC. Although FGF19 is not necessarily a substitute for existing markers, it may help improve the prognosis in HCC patients owing to its resourceful use in various aspects of HCC management and treatment.

scholarly journals Serum Levels of Fibroblast Growth Factor 19 Are Inversely Associated with Coronary Artery Disease in Chinese Individuals

PLoS ONE ◽  
2013 ◽  
Vol 8 (8) ◽  
pp. e72345 ◽  
Author(s):  
Yaping Hao ◽  
Jian Zhou ◽  
Mi Zhou ◽  
Xiaojing Ma ◽  
Zhigang Lu ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Serum Levels ◽  
Fibroblast Growth ◽  
Artery Disease ◽  
Fibroblast Growth Factor 19

Fibroblast Growth Factor 19 Serum Levels: Relation to Renal Function and Metabolic Parameters

2009 ◽  
Vol 42 (03) ◽  
pp. 178-181 ◽  
Author(s):  
M. Reiche ◽  
A. Bachmann ◽  
U. Lössner ◽  
M. Blüher ◽  
M. Stumvoll ◽  
...  
Keyword(s):  
Renal Function ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Serum Levels ◽  
Metabolic Parameters ◽  
Fibroblast Growth ◽  
Fibroblast Growth Factor 19

scholarly journals Axial spondyloarthritis and inflammatory bowel disease: association between disease activity and endothelial dysfunction markers

2021 ◽  
Author(s):  
Hanna Przepiera-Będzak ◽  
Katarzyna Fischer ◽  
Marek Brzosko
Keyword(s):  
Inflammatory Bowel Disease ◽  
Growth Factor ◽  
Endothelial Dysfunction ◽  
Disease Activity ◽  
Bowel Disease ◽  
Axial Spondyloarthritis ◽  
Human Leukocyte ◽  
Serum Levels ◽  
Fetuin A ◽  
Inflammatory Bowel

Abstract Objective We aimed to assess patients with axial spondyloarthritis (axSpA) and inflammatory bowel disease (IBD) for disease activity and serum markers of endothelial dysfunction. Methods We studied 161 patients (123 males, 38 females) with axSpA: 153 with ankylosing spondylitis and 8 with non-radiographic axSpA, and 30 healthy controls (HC). We collected: age; sex; disease duration; extra-articular symptoms (IBD and acute anterior uveitis), comorbidities; human leukocyte antigen B27 status; and treatment. We measured serum interleukin (IL)-6, interleukin-18, IL-23, vascular endothelial growth factor (VEGF) epidermal growth factor (EGF), asymmetric dimethylarginine (ADMA), endothelin-1 (ET-1), and fetuin-A levels. Results IBD was diagnosed in 19 (11.8%) patients with axSpA. Compared to patients with axSpA without IBD, those with IBD had higher serum C-reactive protein (CRP) level (p = 0.05), erythrocyte sedimentation rate (ESR) (p = 0.005), and serum ET-1 levels (p = 0.01). In patients with axSpA and IBD, ET-1 levels correlated positively with CRP level (p = 0.006) and ESR (p = 0.02), and ADMA levels with visual analog scale scores (p = 0.01). Patients with axSpA and IBD had higher serum levels of IL-6 (p = 0.01), IL-18 (p = 0.005), and ADMA (p = 0.01) and lower serum levels of fetuin-A (p = 0.01) than did controls. Conclusions Patients with axSpA and IBD had higher levels of disease activity, as assessed by ESR and CRP and ET-1 levels, than did patients with axSpA without IBD. Compared to HC, patients with axSpA and IBD had increased IL-18, ADMA levels and decreased fetuin-A level.

Sign in / Sign up

Export Citation Format

Share Document